What is Senisca?
Senisca operates at the intersection of advanced molecular biology and regenerative medicine. The company specializes in the development of RNA senotherapeutics, a novel class of drugs designed to target the causative drivers of cellular aging. Unlike traditional approaches that merely manage symptoms, Senisca's platform technology focuses on the underlying biology of senescence, effectively reversing the aging process at the cellular level. This unique market position allows the firm to address a wide spectrum of age-related diseases, offering a transformative potential that has attracted significant interest from deep-tech and longevity-focused venture capital firms. By leveraging its academic roots and rigorous scientific methodology, Senisca is establishing a new paradigm in the treatment of chronic conditions associated with biological decline.
How much funding has Senisca raised?
Senisca has raised a total of $7.2M across 2 funding rounds:
Angel/Seed
$2.5M
Other Financing Round
$4.7M
Angel/Seed (2022): $2.5M with participation from Longevity Tech Fund, Emerging Longevity Ventures, R42 Fund, and Trend Ventures
Other Financing Round (2024): $4.7M led by APEX Ventures and R42 Group
Key Investors in Senisca
APEX Ventures
APEX Ventures is a venture capital firm focused on deep-tech and medical innovations, aiming to build the next generation of world-leading companies through disruptive technology and commercialization guidance.
R42 Group
R42 Group is a venture capital fund and institute that supports deep science ventures from the pre-seed inventing stage to growth stage, with a specific focus on transformative biotechnology and AI.
Emerging Longevity Ventures
Emerging Longevity Ventures is an investment firm focused on rejuvenation biotechnology, providing early-stage capital and strategic support to innovative startups in the longevity sector.
What's next for Senisca?
Looking ahead, the recent capital influx will be instrumental in advancing Senisca's lead candidates through critical preclinical milestones and toward human clinical trials. The company is expected to prioritize the expansion of its R&D infrastructure and the strengthening of its intellectual property portfolio, ensuring a competitive edge in the global biotech landscape. As the firm matures, strategic partnerships with pharmaceutical incumbents may become a focal point for commercialization efforts. The focus remains on validating the efficacy of its RNA-based interventions, with the ultimate goal of delivering breakthrough therapies that redefine the standard of care for age-related health challenges. Investors will be closely monitoring the company's progress in translating its laboratory successes into scalable, clinical-grade solutions.
See full Senisca company page
